Karyopherins; Receptors, Cytoplasmic and Nuclear; exportin 1 protein; Cell Differentiation; Erythroblasts; Erythropoiesis; Humans; Karyopherins/genetics; Receptors, Cytoplasmic and Nuclear/genetics; beta-Thalassemia/drug therapy/genetics
Abstract :
[en] β-thalassemia major (β-TM) is an inherited hemoglobinopathy caused by a quantitative defect in the synthesis of β-globin chains of hemoglobin, leading to the accumulation of free a-globin chains that aggregate and cause ineffective erythropoiesis. We have previously demonstrated that terminal erythroid maturation requires a transient activation of caspase-3 and that the chaperone Heat Shock Protein 70 (HSP70) accumulates in the nucleus to protect GATA-1 transcription factor from caspase-3 cleavage. This nuclear accumulation of HSP70 is inhibited in human β-TM erythroblasts due to HSP70 sequestration in the cytoplasm by free a-globin chains, resulting in maturation arrest and apoptosis. Likewise, terminal maturation can be restored by transduction of a nuclear-targeted HSP70 mutant. Here we demonstrate that in normal erythroid progenitors, HSP70 localization is regulated by the exportin-1 (XPO1), and that treatment of β-thalassemic erythroblasts with an XPO1 inhibitor increased the amount of nuclear HSP70, rescued GATA-1 expression and improved terminal differentiation, thus representing a new therapeutic option to ameliorate ineffective erythropoiesis of β-TM.
Disciplines :
Hematology
Author, co-author :
Guillem, Flavia; INSERM UMR 1163, CNRS ERL 8254, Laboratory of Cellular and Molecular Mechanisms
Dussiot, Michaël; INSERM UMR 1163, CNRS ERL 8254, Laboratory of Cellular and Molecular Mechanisms
Colin, Elia; INSERM UMR 1163, CNRS ERL 8254, Laboratory of Cellular and Molecular Mechanisms
Suriyun, Thunwarat; INSERM UMR 1163, CNRS ERL 8254, Laboratory of Cellular and Molecular Mechanisms
Arlet, Jean Benoit; INSERM UMR 1163, CNRS ERL 8254, Laboratory of Cellular and Molecular Mechanisms
Goudin, Nicolas; US24, Cell Imaging Platform, Necker Federative Structure of Research
Marcion, Guillaume ; Université de Liège - ULiège > GIGA > GIGA I3 - Hematology ; INSERM, Unité Mixte de Recherche 866, Equipe Labellisée Ligue Contre le Cancer
Seigneuric, Renaud; INSERM, Unité Mixte de Recherche 866, Equipe Labellisée Ligue Contre le Cancer
Causse, Sebastien; INSERM, Unité Mixte de Recherche 866, Equipe Labellisée Ligue Contre le Cancer
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Zermati Y, Garrido C, Amsellem S, et al. Caspase activation is required for terminal erythroid differentiation. J Exp Med. 2001; 193(2):247-254.
Ribeil J-A, Zermati Y, VandekerckhoveJ, et al. Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. Nature. 2007;445(7123):102-105.
Arlet J-B, Ribeil J-A, Guillem F, et al. HSP70 sequestration by free a-globin promotes ineffective erythropoiesis in β-thalassaemia. Nature. 2014;514(7521):242-246.
Kudo N, Wolff B, Sekimoto T, et al. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp Cell Res. 1998;242(2):540-547.
Nishi K, Yoshida M, Fujiwara D, Nishikawa M, Horinouchi S, Beppu T. Leptomycin B targets a regulatory cascade of crm1, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression. J Biol Chem. 1994; 269(9):6320-6324.
Lui K, Huang Y. RanGTPase: a key regulator of nucleocytoplasmic trafficking. Mol Cell Pharmacol. 2009;1(3):148-156.
Hattangadi SM, Martinez-Morilla S, Patterson HC, et al. Histones to the cytosol: exportin 7 is essential for normal terminal erythroid nuclear maturation. Blood. 2014; 124(12):1931-1940.
Mathias LA, Fisher TC, Zeng L, et al. Ineffective erythropoiesis in beta-thalassemia major is due to apoptosis at the polychromatophilic normoblast stage. Exp Hematol. 2000;28(12):1343-1353.
Hu J, Liu J, Xue F,et al. Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo. Blood. 2013; 121(16): 3246-3253.
An X, Schulz VP, Li J, et al. Global transcriptome analyses of human and murine terminal erythroid differentiation. Blood. 2014;1 23(22):3466-3477.
Gautier E-F, Ducamp S, Leduc M, et al. Comprehensive Proteomic Analysis of Human Erythropoiesis. Cell Rep. 2016; 16(5):1470-1484.
Fukuda M, Asano S, Nakamura T, et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature. 1997;390(6657):308-311.
Xu D, Farmer A, Chook YM. Recognition of nuclear targeting signals by Karyopherin-β proteins. Curr Opin Struct Biol. 2010; 20(6):782-790.
Pinello L, Xu J, Orkin SH, Yuan G-C. Analysis of chromatin-state plasticity identifies cell-type-specific regulators of H3K27me3 patterns. Proc Natl Acad Sci U S A. 2014;111(3):344-353.
Etchin J, Sun Q, Kentsis A, et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia. 2013;27(1):66-74.
Lapalombella R, Sun Q, Williams K, et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012; 120(23): 4621-4634.
Etchin J, Sanda T, Mansour MR, et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013;161(1):117-127.
Kojima K, Kornblau SM, Ruvolo V, et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013; 121(20):4166-4174.
Walker CJ, Oaks JJ, Santhanam R, et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 2013;122(17):3034-3044.
Wettersten HI, Landesman Y, Friedlander S, Shacham S, Kauffman M, Weiss RH. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth. PloS One. 2014;9(12):1-15.
Ranganathan P, Yu X, Na C, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012;120(9):1765-1773.
Gravina GL, Mancini A, Sanita P, et al. KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models. BMC Cancer. 2015;15:941-960.
Tai Y-T, Landesman Y, Acharya C, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28(1):155-165.
Zeng X-C, Bhasin S, Wu X, et al. Hsp70 dynamics in vivo: effect of heat shock and protein aggregation. J Cell Sci. 2004;117(Pt 21):4991-5000.
Frisan E, Vandekerckhove J, de Thonel A, et al. Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. Blood. 2012;119(6): 1532-1542.
Gastou M, Rio S, Dussiot M, et al. The severe phenotype of Diamond-Blackfan anemia is modulated by heat shock protein 70. Blood Adv. 2017;1(22):1959-1976.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.